Boston Scientific (NYSE:BSX) Given New $100.00 Price Target at Jefferies Financial Group

Boston Scientific (NYSE:BSX) had its target price trimmed by Jefferies Financial Group from $110.00 to $100.00 in a report published on Wednesday morning, MarketBeat Ratings reports. The firm currently has a buy rating on the medical equipment provider’s stock.

Other research analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a “buy” rating and set a $97.00 target price on shares of Boston Scientific in a report on Monday, March 30th. Morgan Stanley dropped their target price on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Canaccord Genuity Group dropped their target price on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Evercore dropped their target price on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Finally, BTIG Research reiterated a “buy” rating on shares of Boston Scientific in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $101.04.

Boston Scientific Stock Up 9.1%

Shares of Boston Scientific stock opened at $64.95 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific has a 1 year low of $59.38 and a 1 year high of $109.50. The firm’s 50-day moving average is $68.87 and its two-hundred day moving average is $86.16. The stock has a market cap of $96.53 billion, a price-to-earnings ratio of 33.48, a PEG ratio of 0.92 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the prior year, the business earned $0.75 EPS. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts expect that Boston Scientific will post 3.45 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

Several hedge funds have recently modified their holdings of BSX. Financial Consulate Inc. purchased a new stake in shares of Boston Scientific during the third quarter valued at about $25,000. Murphy & Mullick Capital Management Corp raised its position in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the 2nd quarter valued at approximately $26,000. Swiss RE Ltd. purchased a new position in shares of Boston Scientific in the 4th quarter valued at approximately $26,000. Finally, Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific in the 4th quarter valued at approximately $26,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results beat and solid top-line growth — Q1 revenue of ~$5.20B and adjusted EPS $0.80 topped estimates and showed 11.6% sales growth, which underpins the bullish reaction. Boston Scientific announces results for first quarter 2026
• Positive Sentiment: Analysts largely kept Buy ratings and reaffirmed long‑term upside (Jefferies, Barclays kept constructive views despite trimming PTs), supporting investor confidence. Balancing Near-Term Guidance Cuts With Long-Term Growth Drivers
• Neutral Sentiment: Several firms trimmed price targets (e.g., Barclays, Jefferies, Stifel lowered PTs to ~$85–$100) — still implying meaningful upside from current levels, but reflecting a nearer‑term reset. Benzinga coverage of analyst updates
• Neutral Sentiment: Unusually large options activity and heavy trading volume signaled speculative and institutional positioning into the print, adding to intraday momentum. Why Is Boston Scientific Stock Soaring Wednesday?
• Negative Sentiment: Management cut FY‑2026 and Q2 guidance (EPS and revenue ranges came in below consensus), which is a clear headwind for near‑term expectations. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Multiple class‑action lawsuits and investor alerts were filed/announced, creating legal overhang and potential costs or distraction for management. BSX Investor Alert: Securities Fraud Lawsuit

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.